Laguna

Laguna is transforming immunotherapy, pushing the field beyond antibody and engineered cell therapies to complete systems-level approaches that will signifcantly improve the outcomes for patients with immense unmet need. Laguna's lead therapy enters the clinic this year, where it will be evaluated in patients with AML, allowing them access to the benefits of the immunotherapy revolution. The company has gone from creation to active clinical study in less than 4 years for less than $5M. This extreme capital efficiency will lead out outsized therapeutic impact and investor returns.